|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 14/545 | (2006.01) |
| A61P 19/02 | (2006.01) |
| (11) | Number of the document | 2598526 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11749612.5 |
| Date of filing the European patent application | 2011-07-29 | |
| (97) | Date of publication of the European application | 2013-06-05 |
| (45) | Date of publication and mention of the grant of the patent | 2018-09-05 |
| (46) | Date of publication of the claims translation | 2018-10-10 |
| (86) | Number | PCT/US2011/045995 |
| Date | 2011-07-29 |
| (87) | Number | WO 2012/016203 |
| Date | 2012-02-02 |
| (30) | Number | Date | Country code |
| 201161493966 P | 2011-06-06 | US | |
| 201161436178 P | 2011-01-25 | US | |
| 201161493967 P | 2011-06-06 | US | |
| 201161436184 P | 2011-01-25 | US | |
| 368799 P | 2010-07-29 | US |
| (72) |
BARNES, Thomas, M., US
HOU, Jinzhao, US
KING, Bracken, M., US
|
| (73) |
Buzzard Pharmaceuticals AB,
Karolinska Science Park, Fagdevreten 2, 171 65 Solna,
SE
|
| (74) |
Vitalija BANAITIENĖ,
UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius,
LT
|
| (54) | Chimeriniai IL-1 receptoriaus I tipo agonistai ir antagonistai |
| CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS |
| Payment date | Validity (years) | Amount | |
| 2025-07-01 | 15 | 289.00 EUR |
| 2026-07-29 |